TCBPW TC BIOPHARM (HOLDINGS) PLC C/WTS 08/02/2027 (TO PUR ADS)
- 0.0163
- -0.0080-32.99%
TC BIOPHARM (HOLDINGS) PLC C/WTS 08/02/2027 (TO PUR ADS) News
TCBP Increasing Treatment Capacity With Expanded Manufacturing Process
TCBP Announces Exercise of Series D Warrants For Cash
TC BioPharm Chief Executive Officer, Bryan Kobel Featured on 'The Big Biz Show'
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing...
TC Biopharm (NASDAQ:TCBPW) Trading Up 35.8%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were up 35.8% during trading on Monday . The company traded as high as $0.12 and last traded at $0.11. Approximately 22,505 shares changed
TC Biopharm (NASDAQ:TCBPW) Shares Down 9.8%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were down 9.8% during mid-day trading on Friday . The stock traded as low as $0.11 and last traded at $0.11. Approximately 1,500 shares tr
TC Biopharm (NASDAQ:TCBPW) Stock Price Down 29.5%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price was down 29.5% during trading on Wednesday . The stock traded as low as $0.12 and last traded at $0.14. Approximately 15,304 shares
TC Biopharm (NASDAQ:TCBPW) Trading Down 29.5%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating)'s stock price traded down 29.5% during mid-day trading on Wednesday . The company traded as low as $0.12 and last traded at $0.14. 15,304 shares
TC BioPharm Shares Halted On Circuit Breaker; Stock Trading Lower During The Company's Shareholder Update Conference Call
Conference Call to be held on Tuesday, February 21st, 2023 at Noon ET EDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASD
TC BioPharm Announces Publication of Paper in AML Research Highlighting the Company's Development of Allogeneic Gamma-Delta T Cell Therapies
TC BioPharm Announces New Chair Of The Board, Arlene Morris
TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer,
TC BioPharm to Reschedule Shareholder Update Call and Webcast
Conference Call to be held on Tuesday, February 21st, 2023 at Noon ET EDINBURGH, Scotland, Feb. 13, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP)
TC BioPharm Announces Hiring of Chief Clinical Officer Bree Harlin to Lead Global Clinical Division
Will oversee expansion of U.S. FDA Clinical TrialsEDINBURGH, Scotland, Jan. 30, 2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical
TC BioPharm to Host Shareholder Update Call
TC BioPharm Receives Notice of Non-compliance With NASDAQ's Listing Rule 5550(b)(1)
TC BioPharm Announces Strategic Collaboration To Advance Gamma Delta T Cells In Oncology
Endeavor to focus on expanding understanding of gamma-delta T cells in oncological settings EDINBURGH, Scotland, Jan. 17, 2023 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company
TC BioPharm Announces Closing of $7.35 Million Private Placement
TC BioPharm Announces $7.35 Million Private Placement
TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating Its Lead Compound, OmnImmune, In Patients With Acute Myeloid Leukemia
3 Patients Dosed in 5 Patient Safety CohortEDINBURGH, Scotland, Nov. 22, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage
TC BioPharm to Present at Upcoming Investor Conferences
TC BioPharm Receives MHRA Approval For 18-Month Extrapolated Shelf-Life Of Allogeneic Cell Therapy Product, OmnImmune
EDINBURGH, Scotland, Sept. 13, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ:TCBP) (NASDAQ:TCBPW), a clinical stage biotechnology company developing platform
Analysis
Price Target
No Data
